The Biomarker Breakdown
Could AMD be diagnosed through blood plasma analysis?
Ruth Steer |
It’s a classic “chicken and egg” scenario. When retinal diseases like age-related macular degeneration (AMD) strike, early diagnosis and intervention give the best prognosis and visual outcomes. But in reality, retinal disease cannot be diagnosed until structural changes are seen, and some patients only present at ophthalmology clinics when the visual symptoms – and the underlying pathology – are at an advanced stage. Now, a team from Massachusetts Eye and Ear Hospital, Boston, USA, are proposing that metabolomics analysis might hold the key to identifying those at risk during the early stages of disease diagnosis – or even before the disease starts to develop (1).
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!
- I Laíns et al., “Human plasma metabolomics study across all stages of age-related macular degeneration identifies potential lipid biomarkers”, PLoS One, 12, e0177749 (2017). PMID: 28542375.